NKTR vs LLY vs PFE vs BMY vs ABBV

For growth investors, Eli Lilly and Company (LLY) is the stronger pick with 44.

7% revenue growth year-over-year, versus -43. 9% for Nektar Therapeutics (NKTR). Bristol-Myers Squibb Company (BMY) offers the better valuation at 16. 3x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate Nektar Therapeutics (NKTR) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bristol-Myers Squibb Company (BMY) is the cheapest at 16.

3x versus AbbVie Inc. at 85. 5x. On forward P/E, Bristol-Myers Squibb Company is actually cheaper at 8. 9x.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +411.

1%, compared to -72. 3% for Nektar Therapeutics (NKTR). Over 10 years, the gap is even starker: LLY returned +1238% versus NKTR's -59. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 34β versus Nektar Therapeutics's 1. 85β — meaning NKTR is approximately 446% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Pfizer Inc. (PFE) carries a lower debt/equity ratio of 78% versus 3% for Bristol-Myers Squibb Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Eli Lilly and Company (LLY) is pulling ahead at 44.

7% versus -43. 9% for Nektar Therapeutics (NKTR). On earnings-per-share growth, the picture is similar: Bristol-Myers Squibb Company grew EPS 178. 2% year-over-year, compared to -12. 1% for Nektar Therapeutics. Over a 3-year CAGR, LLY leads at 31. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Eli Lilly and Company (LLY) is the more profitable company, earning 31.

7% net margin versus -297. 1% for Nektar Therapeutics — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus -236. 8% for NKTR. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Bristol-Myers Squibb Company (BMY) trades at 8.

9x forward P/E versus 28. 2x for Eli Lilly and Company — 19. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NKTR: 59. 3% to $132. 83.

In this comparison, PFE (6.

5% yield), BMY (4. 4% yield), ABBV (3. 2% yield), LLY (0. 6% yield) pay a dividend. NKTR does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

71), 0. 6% yield, +1238% 10Y return). Nektar Therapeutics (NKTR) carries a higher beta of 1. 85 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LLY: +1238%, NKTR: -59. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NKTR is a small-cap quality compounder stock; LLY is a large-cap high-growth stock; PFE is a mid-cap income-oriented stock; BMY is a mid-cap deep-value stock; ABBV is a large-cap income-oriented stock. LLY, PFE, BMY, ABBV pay a dividend while NKTR does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.